Page 182 - Multidisipliner Covid 19

BÖLÜM 10

30 (3):269-271
51. US FDA. Remdesivir letter of EUA. https://www.fda.gov/media/
137564/download (Accessed on May 01.
52. Goldman JD, Lye DC, Hui DS, Marks KM, Bruno R, Montejano R,
Spinner CD, Galli M, Ahn M-Y, Nahass RG (2020) Remdesivir for 5
or 10 days in patients with severe Covid-19. New England Journal of
Medicine
53. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil
AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S (2020) Remdesivir
for the treatment of Covid-19—preliminary report. New England
Journal of Medicine
54. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z,
Lu Q (2020) Remdesivir in adults with severe COVID-19: a randomised,
double-blind, placebo-controlled, multicentre trial. The Lancet

181